Rhythm Pharmaceuticals (RYTM)

• Market cap: $3.16B
• 1 day: -5.61%
• 5 days: -5.46%
• 1 month: -4.58%
• 3 months: -16.76%
• 6 months: -3.42%
• Year to date: -16.76%
• 1 year: 17.15%
• 5 years: 236.25%
• 10 years: 66.67%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

1,417% more call options, than puts

Call options by funds: $26.8M | Put options by funds: $1.76M

121% more first-time investments, than exits

New positions opened: 53 | Existing positions closed: 24

21% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 53

15% more funds holding

Funds holding: 175 [Q3] → 202 (+27) [Q4]

10% more funds holding in top 10

Funds holding in top 10: 10 [Q3] → 11 (+1) [Q4]

2% more capital invested

Capital invested by funds: $3.55B [Q3] → $3.63B (+$86.3M) [Q4]

5.17% less ownership

Funds ownership: 110.77% [Q3] → 105.6% (-5.17%) [Q4]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $66 32% upside
• Avg. target: $73 47% upside
• High target: $81 62% upside

5 analyst ratings

• positive: 5 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Raghuram Selvaraju 35% 1-year accuracy 119 / 341 met price target	40% upside $70	Buy Reiterated	24 Mar 2025
Needham Joseph Stringer 20% 1-year accuracy 24 / 121 met price target	32% upside $66	Buy Maintained	18 Mar 2025
Morgan Stanley Jeffrey Hung 33% 1-year accuracy 9 / 27 met price target	44% upside $72	Overweight Assumed	7 Mar 2025
Stifel Paul Matteis 38% 1-year accuracy 6 / 16 met price target	56% upside $78	Buy Reinstated	5 Mar 2025
Canaccord Genuity Whitney Ijem 30% 1-year accuracy 13 / 43 met price target	62% upside $81	Buy Maintained	27 Feb 2025